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1. Introduction 
Bone metastasis in cancer patients is observed with high clinical frequency and is associated 
not only with cancer pain but also with pathological fractures, restriction of daily activities, 
and other skeletal-related events (SRE). It is therefore an issue with a very decisive effect on 
subsequent quality of life (QOL) (Chow & Bottomley, 2009). The development of 
new therapies for bone metastasis in recent years has allowed progress from the use of 
narcotic formulations, typical of which are the conventional opioid drugs, to treatments 
focused on ‘bone health’ which apply a multidisciplinary approach combining use for 
instance of high-strength bisphosphonate preparations and radionuclide therapy (Satoh et 
al., 2009). In prostate cancer and breast cancer, which have very high incidence of bone 
metastasis, there are many cases where survival of a number of years can be expected even 
at the stage of the illness where this kind of metastasis is present, and the therapeutic 
strategy needs to take account of QOL.  
Each year thousands of men are diagnosed with prostate cancer; it is estimated that about 
192,280 men will be diagnosed with this disease in 2009 (American Cancer Society, 2008).  In 
advanced disease, androgen-deprivation therapy remains the best treatment. After a median 
response of 12 to 24 months, patients develop progressive hormone-refractory prostate 
cancer (HRPC) (Carroll et al., 2002, Chodak et al., 2002). Therefore, the development of new 
therapies with a survival advantage and greater antitumor effects is necessary. Gene therapy 
is a good candidate among new therapies. 
The phase I clinical trial of the combination therapy of osteocalcin promoter-driven herpes-
simplex-virus thymidine kinase (Ad-OC-TK) and valacyclovir (VAL) for the treatment of 
HRPC has been conducted previously at the University of Virginia (Kubo et al., 2003). 
Between August 2003 and March 2006, a phase I/II dose-escalating clinical trial of 
intratumoral injections of Ad-OC-TK was performed on 6 patients with HRPC in order to 
assess the potential toxicity and therapeutic effects of this treatment at Kobe University 
Hospital (Hinata et al., 2006, Shirakawa et al., 2007). In clinical oncological trials, the 
therapeutic effects on the tumor volume and the serum levels of tumor markers are 
frequently used as the primary therapeutic indices. However, recently, the assessment of 
QOL has become an important therapeutic index. Since prostate cancer generally has a 
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protracted natural history, it is particularly important for patients with HRPC to receive 
therapies that preserve or improve QOL, delay the progression of disease caused by severe 
pain, and provide quality-adjusted clinical benefits (Ho et al., 2006).  
Among the QOL assessment systems developed so far are the European Organization for 
Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Core 30 (QLQ-
C30) (Aaronson et al., 1993), Functional Assessment of Cancer Therapy scale-General 
(FACT-G) (Cella et al., 1993) and MOS Short-Form 36-Item Health Survey (SF-36) (Ware & 
Sherbourne, 1992) systems, which have been translated and tested for use in a wide range of 
languages. Modules for quality of life assessment in specific diseases have also been 
developed and applied clinically, for instance EORTC-QLQ-LC13 (Bergman et al., 1994) and 
FACT-L (Cella et al., 1995) for lung cancer, EORTC-QLQ-BR23 (Sprangers et al., 1996) and 
FACT-B (Brady et al., 1997) for breast cancer, and European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire’s prostate cancer-specific module 
(EORTC QLQ-PR25) (da Silva et al., 1993) and FACT-P (Esper et al., 1997) for prostate 
cancer.  However, no QOL module had so far been developed for bone metastasis patients. 
We designed a questionnaire, formulated with reference to the EORTC-QLQ- PR25 
assessment system.  This is the first study, the short-term QOL and bodily pain of patients 
with HRPC who were undergoing a clinical trial involving the direct administration of the 
combination of Ad-OC-TK gene therapy plus VAL intra-lesionally in men with metastatic 
prostate cancer was evaluated.  
2. Patients and methods 
2.1 Eligibility criteria  
The eligibility criteria included the presence of metastatic or locally recurrent prostate 
cancer, histologically confirmed adenocarcinoma, and confirmed disease progression 
despite surgery, radiation, androgen blockage, and/or conventional chemotherapy. Patients 
who were receiving androgen deprivation therapy including anti-androgen therapy 
underwent an at least 4-week anti-androgen withdrawal period before enrollment to 
exclude possible effects of anti-androgen withdrawal syndrome (Scher and Kelly, 1993). 
Luteinizing hormone-releasing hormone(LH-RH) agonist was continued during the anti-
androgen withdrawal period and throughout the study.  Further, each patient included 
must have had a lesion measurable by an imaging examination, and a single selected lesion 
had to be amenable to intralesional injection of the therapeutic agent. 
2.2 Vector and valacyclovir 
The replication-deficient adenoviral vector belongs to subgenus C, serotype 5 (Ad5) with the 
HSV-tk gene under the control of a tumor-restrictive OC promoter in the area of the excised 
E1 region.  Ad-OC-TK was constructed via homologous recombination vector, as described 
previously (Ko et al., 1996). The Good Manufacturing Practice (GMP)-grade adenoviral 
vector (Lusky, 2005) was manufactured and characterized extensively by Molecular 
Medicine Bioservices (Carlsbad, CA) before clinical application.  The oral antiviral agent 
valacyclovir (Valtrex; GlaxoSmithKline, Tokyo, Japan) has been approved in Japan for 
several indications, including treatment for herpes zoster and genital herpes. We used the 
worldwide-approved valacyclovir dosage of 1 g, three times daily (Tyring et al., 2000) in our 
clinical trial. 
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2.3 Study design 
Six patients were divided into the low-dose and high-dose viral vector group (3 patients at 
each dose level). Ad-OC-TK was injected directly into the localized recurrent tumor or the 
bone metastatic lesion under the guidance of transrectal ultrasonography (TRUS) or 
computed tomography (CT). Only one index lesion per patient was selected, typically that 
representing the largest metastasis, causing severe bone pain at the metastatic site, or 
preventing urination by local recurrent tumor. The doses used were 2.5  109 (low-dose 
group: 3 patients) and 2.5  1010 (high-dose group: 3 patients) plaque-forming units (PFU) on 
Day 1 and Day 8. The patients were given 1 g of VAL three times daily for 21 days. 
2.4 Assessment of the short-term QOL and bodily pain  
Since there was no questionnaire for assessing the short-term QOL in patients receiving 
gene therapy for HRPC, we created a questionnaire (Table 1) (Terao, 2009) was created 
based on the EORTC QLQ-PR25 which is widely used to assess QOL in patients of prostate 
cancer. The questionnaire comprised scores evaluating role limitations in work (2 items), 
physical or social functioning (4 items), interpersonal relationships (2 items), emotional 
functioning (3 items), and sleep/vitality (2 items) as well as the global health status (2 
items). A higher median value obtained on the symptom scale indicated a higher number of 
symptoms or problems. All the patients answered the questionnaire by themselves on days 
0 (pretreatment), 14 and 28. The patients indicated how true a statement had been for them 
over the past 14 days using a 4-point scale as follows: 0, not at all; 1, a little bit; 2, quite a bit; 
3, very much. All items were assigned equal weightage. Further, all the patients scored 
themselves on a visual analogue scale (VAS) with regard to their bodily pain on day 0, 14 
and 28 as follows: 0%, they did not experience any bodily pain; 100%, they experienced 
severe bodily pain (EuroQol, 1990).  
 
 
Table 1. Questionnaire. Answer questions from 0-3 (0: not at all; 1: a little bit; 2: quite a bit; 3: 
very much). 
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2.5 Correlation of the change of PSA with QOL and bodily pain  
The correlation of serum prostate-specific antigen (PSA) levels with short-term total QOL 
scores and bodily pain was assessed by measuring the rate of change (%) of the serum PSA 
levels, the short-term total QOL scores, and bodily pain from day 0 to day 28; these values 
were expressed as ⊿PSA, ⊿QOL, and ⊿Pain, respectively (Terao et al., 2009). 
2.6 Statistical analysis  
The short-term QOL scores of patients (nonparametric data) were analyzed by Friedman 
one-way ANOVA. The Spearman test was used to analyze the correlation of ⊿PSA with 
⊿QOL and ⊿Pain. P < 0.05 was considered to be statistically significant. 
3. Results 
3.1 Patient characteristics  
The mean age of the patients was 68 years (range, 63–77 years). The mean pretreatment 
serum PSA level was 222.7 ng/mL (range, 46.6–455.5 ng/mL). Three patients (50%) had 
been diagnosed with poorly differentiated adenocarcinoma and the other 3 (50%) had been 
diagnosed with moderately differentiated adenocarcinoma. All the patients had multiple 
bone metastatic lesions. In addition, 2 patients (33.3 %) had locally recurrent lesions. Two 
patients (33.3%) had undergone radical prostatectomy in the past and all the patients had 
been treated with androgen-deprivation therapy.  
3.2 Short-term QOL and bodily pain  
All 6 patients answered the questionnaires on days 0, 14 and 28. Table 2 (Terao, 2009) shows 
the short-term QOL scores of role limitations in work, physical or social functioning, 
interpersonal relationships, emotional functioning and sleep/vitality along with a total 
score of all items as well as the global health status.). 
 
 
Table 2. Scores of QOL and percent of bodily pain. 
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As compared with day 0, the scores for the global health status (P < 0.05), interpersonal 
relationships (P < 0.01), emotional functioning (P < 0.01) and sleep/vitality (P < 0.01) were 
significantly improved on day 28. Moreover, significant improvements in the short-term 
QOL scores were demonstrated with respect to the role imitations in work (day 14, P < 0.05; 
day 28, P < 0.05) and physical or social functioning (day 14, P < 0.05; day 28, P < 0.01). As 
compared with day 0, the total score of all items was also significantly improved on day 28 
(P < 0.01). Further, as compared with day 0, the bodily pain was significantly reduced on 
day 28 (P < 0.01). 
3.3 Correlation of ⊿PSA with ⊿QOL and ⊿Pain 
Figure 1 shows the changes in the serum PSA levels of all patients from a period of 8 
weeks before (–8 w) to 4 weeks after (4 w) the initial vector injection. The correlation of 
the serum PSA levels with the short-term total QOL scores and bodily pain is shown in 
Figure 2(A) and Figure 2(B), respectively. A significant correlation was observed between 
⊿PSA and ⊿QOL (P < 0.05); however, it was not observed between ⊿PSA and ⊿Pain 
(Terao, 2009). 
4. Discussion 
Bone metastasis is found in 70 to 85% of autopsy cases in malignant tumor patients, and the 
bone is a potential site of metastasis in all cancerous tumors (Tubiana-Hulin, 1991).  In 
recent years, the use of third-generation bisphosphonates and the progress of 
multidisciplinary approaches combining radiotherapy, chemotherapy, and other 
treatments has led to improvement in SREs and prolongation of survival in advanced 
cancers (Saad et al., 2002), so that long-term survival can be expected in prostate cancer, 
breast cancer, multiple myeloma, and other conditions even at the stage where bone 
metastasis is present. In conjunction with this progress, a strategy and response focused 
on long-term quality of life is required beginning from the initial stage of treatment. This is 
now coming to be seen as an important item for assessment when developing novel 
therapies. The present study consisted of a quality of life assessment in prostate 
cancer patients following the novel treatment of gene therapy. 
QOL instruments, including EORTC QLQ-PR25, have been applied in several therapeutic 
trials of prostate cancer (Ho et al., 2006, Cella et al., 2006, Canil et al., 2005). The items in 
these questionnaires include questions regarding urinary conditions, for example 
pollakiuria, dysuria, and macrohematuria. Further, these questionnaires are employed for 
patients of prostate cancer in various stages. In this study, however, patients who have 
undergone various treatments—including radical prostatectomy, androgen-deprivation 
therapy and/or conventional chemotherapy—prior to gene therapy were targeted. 
Further, in 4 patients, the lesions that were injected with the vector were bone metastatic 
lesions alone. This study aimed at assessing the effect of gene therapy on bodily pain 
because most patients suffered pain at the site of vector-injected lesion. Moreover, there 
have been no questionnaires that assess QOL in patients receiving gene therapy for 
HRPC. Taking the above into consideration, a questionnaire based on EORTC QLQ-PR25 
questionnaire (Table 1) was created and bodily pain was assessed by using VAS (Tearo et 
al., 2009). 
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Fig. 1. The change of serum PSA level in all patients from before 8weeks (-8w) to after 
4weeks (4w) of gene therapy.  
 
 
 
Fig. 2. (A) The correlation of PSA levels with short-term total QOL scores. (B) The 
correlation of PSA levels with bodily pain. Both were assessed by measuring the rate of 
change (%) of the serum PSA levels, the short-term total QOL scores, and bodily pain from 
day 0 to day 28; these values were expressed as ⊿PSA, ⊿QOL, and ⊿Pain, respectively. 
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Recently QOL is increasingly being recognized as a measure for assessing outcomes of 
therapeutic trials. Further, the assessment of the clinical effects of therapy on QOL is 
indispensable to the evaluation of therapeutic trials (Fayers & Bottomley, 2005). In several 
therapeutic trials for prostate cancer, the assessment of patients’ QOL is incorporated as a 
therapeutic index. In this study, it was demonstrated that Ad-OC-TK plus VAL treatment 
significantly improved the short-term QOL scores and the total score using the modified 
questionnaire statistically correlated between ⊿PSA and ⊿QOL (Figure 2(A)). Therefore, 
although it will be necessary to compare the changes in QOL scores using the modified 
questionnaire to the changes in QOL scores using other typical questionnaires that are used 
for patients of HRPC, it is considered that the QOL of patients receiving Ad-OC-TK plus 
VAL treatment is worth assessing as a therapeutic index. Further, significant improvements 
in bodily pain were also observed. It is suggested that the clinical improvements may 
contribute to a significant improvement in bodily pain. Since the tumors of these patients 
displayed disease progression despite surgery, radiation, androgen-deprivation therapy 
and/or conventional chemotherapy, the serum PSA levels of all patients were very high 
prior to gene therapy. Following gene therapy, the serum PSA levels decreased in 2 patients, 
no change was observed in 1 patient and they were slightly increased in 2 patients (Figure 
2(A)). Further, the induction of cell apoptosis in the vector-injected lesions of 5 patients 
examined by anti-ssDNA antibody staining on day 28 was also observed. However, a 
correlation between ⊿PSA and ⊿Pain was not demonstrated in spite of the clinical effects 
observed in the vector-injected lesion (Figure 2(B)). In this study, the Ad-OC-TK vector was 
injected directly into one single localized recurrent tumor or bone metastatic lesion despite 
of the fact that all the patients had multiple bone metastatic lesions. Especially in the case of 
patient 3, the pain in the non-vector injected lesions increased on day 28. This fact might be 
one reason that a correlation between ⊿PSA and ⊿Pain was not demonstrated (Terao et al., 
2009). 
Pain, which has been called the fifth vital sign, has come to be recognized as a crucial factor 
in assessing patient condition in the clinical environment. At the same time, however, pain 
is a subjective phenomenon, which makes it difficult to gain an accurate picture of 
a patient’s pain. It will be important in future to perform diagnosis using more appropriate 
assessment methods. In the assessment of the efficacy of gene therapy as a novel cancer 
therapy, assessment methods emphasizing QOL are likely to receive important attention in 
the future. Since it has been found that the subjective sense of physical well-being in a large 
proportion of Japanese patients is centered not on the self but on external objects such as the 
family or the doctor, it would seem important to assess and select therapies with care, taking 
into account psychological aspects which patients find difficult to express for themselves, 
and basing the process on an assessment of the effect of each therapeutic method on the 
basic QOL. 
5. Conclusion 
It was demonstrated that Ad-OC-TK plus VAL gene therapy improved or preserved the 
short-term QOL and bodily pain of HRPC patients with metastatic or local recurrent 
tumors. These assessments may emerge as the new therapeutic indices of gene therapy for 
HRPC. 
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